DEPLOYDatabase

Robot model

Maestro

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair…

Track Maestro
Manufacturer
Moon Surgical
Form factor
surgical
Maturity
pilot
Lifecycle
active
Deployments
1

Overview

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

Verified vs. claimed

Maturity stage
pilot(Small-scale deployment in controlled or trial conditions.)
Verified deployments
1 deployment on file
Sources on file
4 sources, view all

Key facts

Form factor

Laparoscopic surgical-assistant / collaboration robot

FDA clearance

FDA 510(k) cleared June 5, 2024 (K240598)

Patients treated

More than 1,100 across US and Europe (company-stated, not independently verified)

Funding

Approximately $90 million-plus raised

AI feature

ScoPilot: shipped, FDA-cleared AI for intraoperative scope control, powered by NVIDIA Holoscan with a Predetermined Change Control Plan

Specs

Notes

Verified: Moon Surgical (private; Paris + San Carlos CA; CEO Anne Osdoit; board chair Fred Moll, Intuitive co-founder; backers Sofinnova + NVentures/NVIDIA) makes Maestro, a laparoscopic surgical-ASSISTANT/collaboration robot (holds/positions instruments alongside the surgeon, not a full teleop console). Commercial Maestro FDA 510(k)-cleared Jun 5 2024 (K240598); >1,100 patients treated across US + Europe (company-stated). ~$90M+ raised., AI-substance: genuine SHIPPED AI (notable): ScoPilot is a genuine SHIPPED, FDA-cleared AI feature (intraoperative scope control via NVIDIA Holoscan), with a PCCP - not merely demonstrated. This distinguishes Maestro from the teleop-only platforms in this cohort. Maestro itself is a collaborative/assist robot (an honest distinction from full master-slave teleop)., CORRECTION (pathway): Maestro went the 510(k) route (K240598), NOT de novo (the dispatch hypothesized de novo). De novo around that time was Virtual Incision/MIRA and MMI/Symani - different companies., Claimed but NOT verified: CE mark status/date (unverified this pass); exact installed-system count; the 'industry's first AI on a commercial surgical robot' superlative (marketing); the >1,100-patients figure (company-sourced).

Console

not a full master-slave teleoperation console

Products

Maestro: a laparoscopic surgical-assistant platform (holds/positions instruments + endoscope alongside the surgeon). ScoPilot: shipped AI software (NVIDIA Holoscan-powered) for intraoperative scope control. Commercial Maestro FDA 510(k) K240598 cleared Jun 5 2024; ScoPilot FDA-cleared 2025 with a Predetermined Change Control Plan (PCCP).

Form Factor

surgical (laparoscopic surgical-assistant / collaboration robot: holds + positions instruments alongside the surgeon; not full master-slave teleop)

Fda clearance

FDA 510(k) clearance under K240598 on June 5, 2024

Clearance body

FDA

Procedure types

laparoscopic

Data & sources

Press releases

1

Government records

1

Web sources

2

4 sources backing this record.View all →

Availability and pricing

Availability
Not sold (internal use)
Price
$300K to $800K (analyst estimate)as of 2025-01-01
Units in field
Not disclosed
Sales model
Not disclosed
Lead time
Not disclosed

Pricing

One-time purchase

$300,000 - $800,000 USDanalyst estimateas of 2025-01-01

Source: How Much is a Surgical Robot? (2025 Edition) – R2 Surgical

Price status: actual-sale-price = real published price at time of sale; manufacturer-target = vendor target, not yet realized; analyst-estimate = third-party projection, not a vendor figure; not-announced = no price on record.

Prices verified as of Jan 1, 2025

Deployments (1)

  • Maestro at Jacksonvilleoperational

    Baptist Health in Jacksonville, Florida became the first US site to use the Moon Surgical Maestro system clinically, in September 2023.

Maestro on the deployment map

Where Maestro is verified operating. Explore the deployment map by place and type.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Deployment-verified media (1)

PRIMARY SOURCE
Courtesy of Moon Surgical

Moon Surgical's overview of its Maestro surgical-assistance system. Maestro is operated by the surgical team; its ScoPilot feature automates scope and camera movement, not the surgery.

From deployment: Jacksonville

Regulatory filings (3)

Safety record

No incidents on record for Maestro.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (4)

  1. https://www.prnewswire.com/news-releases/moon-surgical-second-fda-clearance-commercial-maestro
  2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K240598
  3. https://www.biospace.com/moon-surgical-scopilot-fda-nvidia-holoscan
  4. https://www.massdevice.com/moon-surgical-funding-fred-moll/

Compare Maestro

Common questions

What is Maestro?
Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.
How much does Maestro cost?
Maestro is listed at $300,000 to $800,000 on the DEPLOY registry. This is an analyst estimate, not an official price.
How Much is a Surgical Robot? (2025 Edition) – R2 Surgical
Is Maestro actually deployed in the real world?
Yes. Maestro is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Is Maestro autonomous or teleoperated?
Not verified as fully autonomous. Maestro's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.
Who makes Maestro?
Maestro is made by Moon Surgical, based in San Carlos, California, USA, founded in 2020.
Methodology: Claimed (not regulatorily cleared) · 4 sources (2 primary) · last reviewed 2026-07-12

Verification posture

Claimed (not regulatorily cleared)

Cap-flag required

Review state

Drift-flagged

Last reviewed 2026-07-12

1 anchored drift pattern(s); see cap_flags

Maturity + lifecycle

Maturity stage: pilot

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

2
unclassified
Unclassified source
1
primary-company-ir
Company IR disclosure
1
primary-fda-database
FDA database

Cap flags

  • Claim: Moon Surgical Maestro received FDA clearance in December 2023

    Honest status: Moon Surgical Maestro received FDA 510(k) clearance K240598 on June 5, 2024. December 2023 dates circulating in aggregator content are aggregator drift.

    Moon Maestro FDA clearance is K240598 on June 5, 2024, not December 2023.

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Maestro.

Recent coverage

Maestro in third-party press

Moon Surgical wins first FDA 510(k) clearance for surgical robot

Jun 25, 2026

Moon Surgical wins FDA clearance for Maestro

Jun 1, 2025